AVITA Medical (ASX:AVH) Shares Rise 4.06% as Commercial Momentum Builds

Aditi Sarkar

20 August 2026 08:24 PM AEST

AVITA Medical (ASX:AVH) Shares Rise 4.06% as Commercial Momentum Builds

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

AVITA Medical (ASX:AVH) closed at AUD 2.82, up 4.06% on 20 August 2026.
The company develops regenerative medicine solutions for acute wound care, led by RECELL.
Q2 2026 Revenue reached US$21.7 million, up 18% year-on-year and 13% quarter-on-quarter.
Investors continue to monitor RECELL adoption, Medicare reimbursement changes, product expansion and Cash Flow progress.

AVITA Medical (ASX:AVH) shares closed at AUD 2.82, up 4.06% on 20 August 2026. The movement reflects a positive Trading session as investors continue to assess the company’s acute wound care portfolio, commercial execution and pathway towards cash flow breakeven.

Daily share price movements can reflect changes in investor sentiment, trading activity, valuation expectations and broader market conditions. However, a single-session movement does not necessarily indicate a change in the company’s underlying fundamentals, financial position or long-term operating outlook.

AVITA Medical develops regenerative medicine technologies focused on acute wound care. Its flagship RECELL System is designed to prepare autologous skin cell suspension for use in treating burn wounds and full-thickness skin defects. The company also markets Cohealyx and PermeaDerm as part of its broader wound care portfolio.

The broader Australian market closed higher on the day. The S&P/ASX 200 (ASX:XJO) closed at 9,083.80 points, up 0.33% today, while the S&P/ASX 300 (ASX:XKO) closed at 9,019.90 points, up 0.37% today. Within the healthcare sector, the S&P/ASX 200 Health Care (ASX:XHJ) closed at 32,044.30 points, up 1.39% today.

Regenerative wound care platform

AVITA Medical operates within the medical technology sector, focusing on regenerative solutions that support wound healing and tissue repair.

The company’s core product, RECELL, uses a patient’s own skin cells to create a suspension applied to wound sites. The technology is primarily used in acute wound care settings, including burns and complex skin injuries.

Investors generally assess medical technology companies through product adoption, reimbursement pathways, clinical outcomes, regulatory approvals, Manufacturing capability and commercial expansion.

AVITA’s Business model is linked to hospital adoption, physician utilisation and reimbursement frameworks. The company’s growth depends on increasing awareness among healthcare providers and expanding usage across eligible patient groups.

The acute wound care market is influenced by healthcare expenditure, hospital treatment protocols, reimbursement structures and Demand for technologies that can improve clinical workflows.

Q2 2026 performance and commercial update

AVITA Medical’s Q2 2026 results highlighted record quarterly revenue, with net revenue reaching US$21.7 million, up 18% compared with Q2 2025 and 13% compared with Q1 2026. Growth was supported by RECELL adoption, increased utilisation of Cohealyx and PermeaDerm, and continued international revenue contribution.

RECELL generated Q2 revenue of US$18.5 million, representing approximately 11% growth compared with Q1 2026. Cohealyx revenue increased to US$1.7 million, up approximately 16% quarter-on-quarter, while PermeaDerm revenue reached US$0.6 million, up approximately 40% quarter-on-quarter.

Gross profit margin increased to 81.9% in Q2 2026 from 81.2% in Q2 2025. Operating expenses declined to US$24.6 million, down 6% year-on-year, reflecting continued cost management while supporting commercial expansion.

The company reduced net cash use to approximately US$3.2 million during Q2 2026, compared with US$9.9 million in Q1 2026. Cash, cash equivalents and marketable securities stood at approximately US$11.1 million at the end of the quarter.

AVITA increased its full-year 2026 revenue guidance to US$86 million to US$89 million, compared with previous guidance of US$80 million to US$85 million. The company also expects to achieve cash flow breakeven in Q4 2026.

A key development during the period was the proposed 2027 Medicare payment framework for RECELL. The Centers for Medicare & Medicaid Services (CMS) proposed changes that would introduce a national physician payment framework for the skin cell suspension autograft procedure and increase hospital outpatient and ambulatory surgical centre payment rates, subject to finalisation.

AVITA also continued expanding RECELL utilisation, with total US RECELL Volume increasing to 2,621 units in Q2 2026, supported by physician adoption and increased use of RECELL GO Mini for smaller wounds.

Investors continue to monitor whether commercial growth, reimbursement improvements and broader product adoption can support sustained financial performance.

Factors investors generally monitor

AVITA Medical’s performance is influenced by product adoption, reimbursement outcomes, hospital demand, regulatory developments and manufacturing execution.

RECELL utilisation remains a key focus area because commercial growth depends on increasing physician confidence and expanding usage across eligible wound care procedures.

Reimbursement conditions are particularly important for medical technology companies. Changes to Medicare payment frameworks can influence hospital adoption, physician Economics and long-term commercial potential.

Clinical outcomes and healthcare provider acceptance also remain important. Hospitals generally evaluate new technologies based on effectiveness, workflow improvements and economic considerations.

Product portfolio expansion is another area investors monitor. Growth from Cohealyx and PermeaDerm provides additional opportunities beyond RECELL, although commercial adoption remains an important factor.

Cash flow management is also closely watched. Companies transitioning towards profitability are assessed on their ability to grow revenue while controlling operating expenses.

Understanding the share price movement

AVITA Medical’s 4.06% share price increase on 20 August 2026 may reflect changes in investor sentiment, trading activity or positioning within the healthcare sector. However, daily share price movements alone do not necessarily represent changes in the company’s underlying fundamentals.

Healthcare technology stocks can experience short-term Volatility as investors reassess commercial progress, reimbursement developments and future Earnings potential.

For AVITA Medical, investors are likely to continue monitoring RECELL adoption, Medicare payment developments, product expansion and progress towards cash flow breakeven.

Conclusion

AVITA Medical (ASX:AVH) closed at AUD 2.82, up 4.06% on 20 August 2026. The company continues to develop its regenerative wound care platform through RECELL and complementary products.

While the daily share price movement reflects market activity, investors generally assess AVITA through broader factors including revenue growth, product adoption, reimbursement frameworks, operating efficiency and cash generation. Q2 2026 results highlighted record revenue, improved cash utilisation, higher revenue guidance and continued commercial expansion across the company’s wound care portfolio.

FAQs

Q: What was AVITA Medical’s share price movement on 20 August 2026?

A: AVITA Medical (ASX:AVH) closed at AUD 2.82, up 4.06% on 20 August 2026.

Q: What does AVITA Medical do?

A: AVITA Medical develops regenerative wound care technologies, including RECELL, for acute wound treatment applications.

Q: What were AVITA Medical’s Q2 2026 results?

A: AVITA Medical reported Q2 2026 revenue of US$21.7 million, gross profit margin of 81.9% and operating expenses of US$24.6 million.

Q: What is AVITA Medical’s FY26 revenue guidance?

A: AVITA Medical increased FY26 revenue guidance to US$86 million to US$89 million and expects cash flow breakeven in Q4 2026.

Q: What factors influence AVITA Medical’s outlook?

A: Investors generally monitor RECELL adoption, reimbursement changes, clinical acceptance, product expansion, regulatory developments and cash flow progres

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.